Fangzhou Jianke, the 'First Mobile Healthcare Stock,' Announces Strategic Partnership with Tencent to Advance Digital and Intelligent Transformation in Internet Healthcare

On September 19, Fangzhou Pharmaceutical (06086.HK), known as the “first stock in mobile healthcare,” held the 9th H2H Medical Service Ecosystem Conference (hereinafter referred to as the “Ecosystem Conference”) in Shanghai. Themed “Digital Intelligence in Healthcare: Innovation-Driven Development,” the conference featured experts from the pharmaceutical industry, representatives from renowned domestic and international pharmaceutical companies, and frontline practitioners. These guests shared vivid insights from diverse perspectives on topics such as the trillion-yuan internet hospital market, efficient operational models for online physicians, and innovations in digital marketing, thereby providing the industry with ideas and inspiration for innovative development.

Notably, at the ecosystem conference, Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, and Yan Peng, Vice President of Tencent Cloud and Tencent Health, jointly signed a strategic cooperation agreement. The two parties will engage in deep collaboration across multiple fields, including internet healthcare, chronic disease management services, and digital innovation, working together to elevate the overall industry standard and provide users with more efficient and intelligent medical services.

Fangzhou Pharmaceutical, China’s largest online platform for chronic disease management services, is leveraging its exceptional H2H (Hospital-to-Home) smart healthcare ecosystem to drive an industry-wide transformation in health services—from hospitals to homes and from offline to online—through technological empowerment. As a giant in the digital technology sector both in China and globally, Tencent has actively expanded into the healthcare field, providing services to medical institutions, medical insurance providers, and pharmaceutical companies, thereby enhancing the operational efficiency of the entire healthcare system.

Rooted in the industry, serving the public. Fangzhou Pharmaceutical and Tencent share a profound consensus on digital strategy, technological innovation, user experience, and ecosystem collaboration, with aligned visions for serving public health. In 2023, Fangzhou Pharmaceutical and Tencent Cloud collaborated across multiple domains, including cloud infrastructure, private-domain user operations, medical science popularization content, and AIGC (Artificial Intelligence Generated Content).

In 2024, the strategic partnership between the two parties was further deepened. Fangzhou Pharmaceutical and Tencent will fully leverage their respective strengths in their fields to build business linkages through “Tencent Medical Dictionary,” thereby expanding the influence of professional medical science popularization and increasing user reach. Furthermore, both parties will continue to integrate their collaboration on the “Tencent Health Medicine Cabinet.” Relying on WeChat, a national-level social platform, they aim to provide every user and patient with more precise and personalized services, such as medication reminders and disease progression tracking, demonstrating technological warmth and humanistic care.

The renewed collaboration between Fangzhou Pharmaceutical and Tencent has not only sparked innovation but also represents a deep exploration and reshaping of the internet-based healthcare management model.

“Over the past two years, the industry has entered a phase of restructuring, which means that leading enterprises are focusing on building their own capabilities, particularly by persisting in the development of core internet hospitals and chronic disease management service centers,” emphasized Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, in his keynote speech titled “Deepening Smart Healthcare, Innovating to Lead the Future.” He highlighted that Fangzhou Pharmaceutical has consistently adhered to a development strategy centered on technological innovation and putting users first, earning market recognition through high-quality patient services and professional medical services.

As the “first stock in mobile healthcare,” Fangzhou Pharmaceutical successfully listed on the Main Board of the Hong Kong Stock Exchange this July. Data shows that Fangzhou Pharmaceutical has attracted 45.6 million registered users and 217,000 registered doctors, conducted over 8,000 live broadcasts for popular science education, participated in research projects funded by the National Natural Science Foundation of China, and obtained 23 artificial intelligence patents... Seizing opportunities under the digital wave, Fangzhou Pharmaceutical delivered a “report card” in 2024 that boosted industry confidence. In addition, Fangzhou Pharmaceutical has achieved comprehensive upgrades in businesses such as internet hospitals, artificial intelligence algorithms, supply chain links, and health science popularization matrices, embarking on the journey of Internet Healthcare 2.0 with digital intelligence.

It is reported that, leveraging its internet hospital and dual-channel pharmacies, Fangzhou Pharmaceutical has fully enabled online medical insurance settlement in Guangzhou. In the future, it will continue to list more key products to alleviate the financial burden on patients. Meanwhile, Fangzhou Pharmaceutical is committed to establishing a premier domestic medical service center, closely integrating its internet hospital with medical services. By comprehensively optimizing the pharmaceutical supply chain, the company aims to bring new hope to patients through greater access to innovative drugs.

The strategic partnership between Fangzhou Pharmaceutical and Tencent will help realize the vision of empowering the healthcare industry through technology, deliver higher-quality products and services to the public, and contribute to building a healthy future for China’s internet healthcare sector. By staying true to its original mission, this collaboration aims to inject new momentum into the future development of the healthcare industry.